Effects of Pyrotinib combined with Trastuzumab in treatment of human epidermal growth factor receptor 2 positive breast cancer
Objective:To observe effects of Pyrotinib combined with Trastuzumab in treatment of patients with human epidermal growth factor receptor2(HER2)positive breast cancer.Methods:A prospective study was conducted on 64 patients with HER2 positive breast cancer admitted to the hospital from 2020 to 2022.According to the random number table method,they were divided into control group and observation group,32 cases in each group.The control group was treated with Trastuzumab,while the observation group was treated with Pyrotinib on the basis of that of the control group.The clinical efficacy(disease control rate,objective remission rate),the median progression-free survival,the overall survival rate,the levels of inflammatory factors[tumor necrosis factor-α(TNF-α),interleukin-8(IL-8),interleukin-1β(IL-1β)]and tumor markers[carcinoembryonic antigen(CEA),carbohydrate antigen 15-3(CA15-3),vascular endothelial growth factor(VEGF)]before and after the treatment,and the incidence of adverse reactions were compared between the two groups.Results:The disease control rate of the observation group was 93.75%(30/32),which was higher than that of the control group(68.75%,22/32);the objective remission rate of the observation group was 78.12%(25/32),which was higher than that of the control group(53.12%,17/32);and the differences were statistically significant(P<0.05).The median progression-free survival of the observation group was longer than that of the control group;the overall survival rate was 56.25%(18/32),which was higher than 25.00%(8/32)of the control group;and the differences were statistically significant(P<0.05).After the treatment,the levels of TNF-α,IL-8 and IL-1β in the observation group were lower than those in the control group,and the differences were statistically significant(P<0.05).After the treatment,the levels of CEA,CA15-3 and VEGF in the observation group were lower than those in the control group,and the differences were statistically significant(P<0.05).However,there was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusions:Pyrotinib combined with Trastuzumab in the treatment of HER2 positive breast cancer can improve the disease control rate,the objective remission rate and the overall survival rate,prolong the median progression-free survival,and reduce the levels of inflammatory factors and tumor markers.Moreover,it is superior to simple Trastuzumab treatment.
Breast cancerHuman epidermal growth factor receptor2PyrotinibTrastuzumabSurvival rateInflammatory factorTumor marker
万方数据
维普
